Trials / Conditions / Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity

Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity

11 registered clinical trials studyying Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity.

Status	Trial	Sponsor	Phase
Completed	18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis NCT01806675	Sanjiv Sam Gambhir	Phase 1 / Phase 2
Completed	Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cance NCT01637194	Fox Chase Cancer Center	Phase 1
Completed	Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Pri NCT00492089	National Cancer Institute (NCI)	Phase 2
Completed	Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Nec NCT00397384	National Cancer Institute (NCI)	Phase 1
Completed	Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck NCT00470496	Roswell Park Cancer Institute	Phase 1
Completed	Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidne NCT00101348	National Cancer Institute (NCI)	Phase 1 / Phase 2
Completed	Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors NCT00089362	National Cancer Institute (NCI)	Phase 1
Completed	Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Can NCT00068497	National Cancer Institute (NCI)	N/A
Completed	Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction NCT00030498	National Cancer Institute (NCI)	Phase 1
Completed	7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid NCT00031681	National Cancer Institute (NCI)	Phase 1
Completed	Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and NCT00023959	National Cancer Institute (NCI)	Phase 1